小无功能胰腺神经内分泌肿瘤保留实质与肿瘤学切除的长期结局:大型多中心队列研究
该回顾性多中心队列纳入810例<3cm散发性无功能胰腺神经内分泌肿瘤患者,比较保留实质切除(PSR)与肿瘤学切除的围术期及长期结局。经病例匹配后,PSR组微创比例更高、出血更少、手术时间更短,但淋巴结清扫数更少;两组总体并发症、无病生存与总生存相当,中央胰腺切除并发症较高。
要点
- 对于<3cm无功能PNET,PSR与肿瘤学切除的长期无病生存和总生存相当。
- PSR围术期优势明显:微创比例更高、出血更少、手术时间更短。
- 中央胰腺切除的术后并发症率高于肿瘤学切除,需权衡选择。
核心结论
- 在<3cm无功能PNET中,保留实质切除和保留淋巴结切除与更少出血、更短手术时间和更低并发症率相关,且长期肿瘤学结局相似。
研究设计与样本
- 回顾性分析4个高容量胰腺中心2000至2021年前瞻性收集的临床病理数据,共810例<3cm散发性无功能PNET患者。
- 121例(14.9%)行剜除术,100例(12.3%)行中央胰腺切除,589例(72.7%)行肿瘤学切除。
- 按肿瘤大小进行病例对照匹配后,每组各221例。
主要发现
- PSR组微创手术比例32.6% vs 13.6%(P<0.001),术中出血358 vs 511 ml(P<0.001),手术时间180 vs 330分钟(P<0.001)。
- PSR组淋巴结清扫数1.4 vs 9.9(P<0.001),但阳性淋巴结数1.1 vs 0.9(P=0.808)无差异。
- 总体并发症率PSR与肿瘤学切除38.5% vs 48.2%(P=0.090),中央胰腺切除38.5% vs 56.6%(P=0.003)。
- 中位无病生存190.5 vs 195.2个月(P=0.506),总生存197.9 vs 192.6个月(P=0.372)。
- 810例中136例(16.7%)未清扫淋巴结,其并发症率39.7% vs 56.9%(P=0.008),无病生存197.1 vs 191.9个月(P=0.837),总生存200 vs 195.1个月(P=0.827)。
临床怎么用
- 对于<3cm无功能PNET,保留实质切除可作为安全选项,围术期恢复更优且长期肿瘤学结局不劣。
- 中央胰腺切除术后并发症较高,选择术式时需个体化评估。
- 未清扫淋巴结患者长期生存与N0患者相似,支持在选择性病例中省略淋巴结清扫。
局限性
- 回顾性研究设计,非前瞻性随机对照。
- 数据来自4个高容量中心,可能存在选择偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: The role of parenchyma-sparing resections (PSR) and lymph node dissection in small (<3 cm) nonfunctional pancreatic neuroendocrine tumors (PNET) is unlikely to be studied in a prospective randomized clinical trial. By combining data from 4 high-volume pancreatic centers we compared postoperative and long-term outcomes of patients who underwent PSR with patients who underwent oncologic resections. METHODS: Retrospective review of prospectively collected clinicopathologic data of patients who underwent pancreatectomy between 2000 and 2021 was collected from 4 high-volume institutions. PSR and lymph node-sparing resections (enucleation and central pancreatectomy) were compared to those who underwent oncologic resections with lymphadenectomy (pancreaticoduodenectomy, distal pancreatectomy). Statistical testing was performed using χ 2 test and t test, survival estimates with Kaplan-Meier method and multivariate analysis using Cox proportional hazard model. RESULTS: Of 810 patients with small sporadic nonfunctional PNETs, 121 (14.9%) had enucleations, 100 (12.3%) had central pancreatectomies, and 589 (72.7%) patients underwent oncologic resections. The median age was 59 years and 48.2% were female with a median tumor size of 2.5 cm. After case-control matching for tumor size, 221 patients were selected in each group. Patients with PSR were more likely to undergo minimally invasive operations (32.6% vs 13.6%, P <0.001), had less intraoperative blood loss (358 vs 511 ml, P <0.001) and had shorter operative times (180 vs 330 minutes, P <0.001) than patients undergoing oncologic resections. While the mean number of lymph nodes harvested was lower for PSR (n=1.4 vs n=9.9, P <0.001), the mean number of positive lymph nodes was equivalent to oncologic resections (n=1.1 vs n=0.9, P =0.808). Although the rate of all postoperative complications was similar for PSR and oncologic resections (38.5% vs 48.2%, P =0.090), it was higher for central pancreatectomies (38.5% vs 56.6%, P =0.003). Long-term median disease-free survival (190.5 vs 195.2 months, P =0.506) and overall survival (197.9 vs 192.6 months, P =0.372) were comparable. Of the 810 patients 136 (16.7%) had no lymph nodes resected. These patients experienced less blood loss, shorter operations ( P <0.001), and lower postoperative complication rates as compared to patients who had lymphadenectomies (39.7% vs 56.9%, P =0.008). Median disease-free survival (197.1 vs 191.9 months, P =0.837) and overall survival (200 vs 195.1 months, P =0.827) were similar for patients with no lymph nodes resected and patients with negative lymph nodes (N0) after lymphadenectomy. CONCLUSION: In small <3 cm nonfunctional PNETs, PSRs and lymph node-sparing resections are associated with lower blood loss, shorter operative times, and lower complication rates when compared to oncologic resections, and have similar long-term oncologic outcomes.
引用
- Bolm L, Nebbia M, Wei AC, et al. Long-term Outcomes of Parenchyma-sparing and Oncologic Resections in Patients With Nonfunctional Pancreatic Neuroendocrine Tumors <3 cm in a Large Multicenter Cohort. Ann Surg. 2022. PMID: 35758433. doi:10.1097/SLA.0000000000005559
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。